Individuals juggling shift work, travel, or caregiving schedules may find that weekly semaglutide helps reduce missed doses and provides steadier appetite control
Although the PIONEER and SUSTAIN studies only examined serious adverse reactions (SAEs) for people taking semaglutide, it is possible that similar reactions could occur after taking other GLP-1 drugs
Others may experience constipation or fatigue, especially as the body adjusts to the medication
Plan your vial supply accordingly to avoid running short during the maintenance phase
GLP-1 medications work with hormone pathways involved in appetite regulation, digestion and metabolic processes
The timeline for the final rule is not specified, but based on typical FDA rulemaking, a final decision could come in late 2026 or early 2027